Cisplatin
From Biocrawler, the free encyclopedia.
|
| |
| Cis-diaminedichloroplatinum(II) | |
| CAS number 15663-27-1 | ATC code L01XA02 |
| Chemical formula | Cl2H6N2Pt |
| Molecular weight | 300.0474 |
| Bioavailability | N/A |
| Metabolism | Nil |
| Elimination half-life | ? |
| Excretion | Renal |
| Pregnancy category | ? |
| Legal status | ? |
| Routes of administration | Intravenous |
Cisplatin or cis-diaminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
| Contents |
Pharmacology
Mode of action
Cisplatin acts by crosslinking DNA in various different ways, making it impossible for rapidly dividing cells to duplicate their DNA for mitosis. The damaged DNA sets off DNA repair mechanisms, which activate apoptosis when repair proves impossible.
Most notable among the DNA changes are the intrastrand GpG adducts which form nearly 90% of the adducts. Other adducts include inter-strand crosslinks and nonfunctional adducts that have been postulated to contribute to its activity. Interaction with cellular proteins has also been advanced as a mechanism of interfering with mitosis, although this is probably not its main action.
Side-effects
Cisplatin has a number of side-effects that can limit its use:
- Nephrotoxicity (kidney damage) is a major concern when cisplatin is prescribed as a chemotherapy agent. The dose therefore has to be tailored to the patient's creatinine clearance (a measure of renal function), and adequate hydration and diuresis is used to prevent renal damage.
- Neurotoxicity (nerve damage) can be anticipated by performing nerve conduction studies before and after treatment.
- Ototoxicity (hearing loss)
- Hair loss, nausea and vomiting
History
As a compound cisplatin was first described by M. Peyrone in 1845. It was rediscovered in the 1960s by Rosenberg et al, who discovered that electrolysis products from a platinum electrode inhibited mitosis in Escherichia coli (E. coli) bacteria.
In the 1970s, a series of experiments were conducted at Michigan State University to test the effects the cis-diaminedichloroplatinum(II), along with other platinum coordinate complexes, on sarcomas artificially implanted in rats. This study found that cis-diaminedichloroplatinum(II) was the most effective out of this group, which started the medicinal career of cisplatin.
Approved for clinical use by the American Food and Drug Administration (FDA) in 1978, it revolutionized the treatment of certain cancers. Detailed studies on its molecular mechanism of action, using a variety of spectrocopic methods including X-ray, NMR and other physico-chemical methods, revealed its ability to form irreversible crosslinks with bases in DNA.
References
- Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698-9. PMID 14287410.
- Peyrone M. Ann Chemie Pharm 1845;51:129.
External links
- Cisplatin: The Invention of an Anticancer Drug (http://chemcases.com/cisplat/index.htm) by Andri Smith
- MedlinePlus page on cisplatin (http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a684036.html)ja:シスプラチン
